BIRC5 and neoplasm: Of the 151 patients with endometrioid cancer, 47 (27.5%) had enhanced survivin expression; of the 147 patients with the mucinous subtype, 82 (55.8%) had enhanced survivin expression; of the 332 patients with the serous subtype, 237 (71.4%) had enhanced survivin expression; of the seven patients with a poorly differentiated tumour, five (71.4%) had enhanced survivin expression; of the 16 patients with an undifferentiated tumour, 11 (67%) had enhanced survivin expression; and of the 16 patients with clear cell carcinoma, seven (43.75%) had enhanced survivin expression.